Amount of eligible individuals: CDEC talked over the uncertainty in the number of sufferers with moderately critical to severe hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some clients that are categorized as obtaining delicate or moderate condition could have a significant